spacer gif spacer gif spacer gif spacer gif spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 30 July 2003
doi: 10.1242/jcs.00693


This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koivisto, L.
Right arrow Articles by Larjava, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koivisto, L.
Right arrow Articles by Larjava, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes

Leeni Koivisto1, Keyhan Alavian1, Lari Häkkinen1, Steven Pelech2, Christopher A. McCulloch3 and Hannu Larjava1,*

1 University of British Columbia, Faculty of Dentistry, Department of Oral Biological and Medical Sciences, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
2 Kinexus Bioinformatics Corporation, Suite 401, 2389 Health Sciences Mall, Vancouver, BC V6T 1Z4, Canada
3 University of Toronto, Faculty of Dentistry, Department of Biological and Diagnostic Sciences, 150 College Street, Toronto, ON M5S 3E2, Canada



View larger version (94K):

[in a new window]
 
Fig. 1. Keratinocyte E-lam formation in mucosal wounds and in vitro. (A) Electron micrograph of migrating keratinocytes in 3-day-old human mucosal wounds. Arrows mark cellular extensions formed by wound keratinocytes. wb, wound bed; kc, keratinocyte. (B) A photograph of primary mouse keratinocytes grown in medium containing fibroblast conditioned medium and EGF (4 ng/ml). Arrows mark E-lams. (C) HaCaT keratinocytes were treated with EGF (4 ng/ml) in DMEM containing 1% FBS for 48 hours and then photographed. Arrows mark E-lams. Scale bar: 10 µm.

 


View larger version (32K):

[in a new window]
 
Fig. 2. Staurosporine-induced E-lam formation in HaCaT keratinocytes. (A) The morphology of HaCaT cells spreading on fibronectin in absence (a) or in presence (b) of staurosporine as visualized by scanning electron microscopy. Extended lamellipodia are marked with arrows and filopodia with arrowheads. Scale bar: 10 µm. Equivalent phase contrast pictures (insets) from crystal violet stained cells were taken using 20x objective. (B) The cells were allowed to spread on fibronectin for 60 minutes in presence of staurosporine (0-100 nM). The cells were fixed and four representative fields in triplicate wells were examined by phase-contrast microscopy using a 20x objective (n=12). The percentage of cells that were spread or forming E-lams out of the total cell number within each field was calculated (mean±s.d.). (C) The cells were allowed to spread on fibronectin for 2 hours and then treated with 50 nM staurosporine for 1 hour or left untreated. For comparison, some of the cells were treated with staurosporine for 3 hours. The cells were fixed, and the percentage of cells that were spread or forming E-lams of the total cell number was calculated as in B (mean±s.d., n=12).

 


View larger version (123K):

[in a new window]
 
Fig. 3. The effect of tyrosine kinase and phosphatase inhibitors on E-lam formation. The cells were allowed to spread on fibronectin for 120 minutes and then not treated (A,B), or treated with 500 µM sodium orthovanadate (C,D), 10 µM herbimycin A (E,F) or 200 µM genistein (G,H) in the presence (B,D,F,H) or absence (A,C,E,G) of 50 nM staurosporine for 60 minutes. The cells were fixed, stained with crystal violet and photographed. E-lams are marked with arrows. Scale bar: 10 µm.

 


View larger version (42K):

[in a new window]
 
Fig. 4. Changes in GSK-3 phosphorylation induced by staurosporine. The cells were allowed to spread on fibronectin for 120 minutes and then treated with 50 nM staurosporine for either 0-60 minutes or left untreated for 60 minutes (C60'). The cell lysates were separated by SDS-PAGE and immunoblotted with antibodies recognizing GSK-3{alpha}/ß phosphorylated on serine 21/9 (A,B), GSK-3{alpha}/ß phosphorylated on tyrosine 279/216 (C) or total GSK-3 (D). The bands visible in A represent GSK-3ß. GSK-3{alpha} phosphorylation followed a similar trend but was much weaker. P-GSK-3{alpha} is visible in B, which represents a longer exposure of A.

 


View larger version (43K):

[in a new window]
 
Fig. 5. The role of GSK-3 in E-lam formation. To investigate the role of GSK-3 in E-lam formation, the cells were treated with LiCl2 (2-40 mM; A) or SB-415286 (1-50 µM; B) in presence or in absence of staurosporine. The percentage of cells that were spread or representing E-lams was calculated. Results (mean±s.d., n=8) of one representative experiment are shown. (*P<0.05; **P<0.01; ***P<0.001.) (C) The morphology of cells treated with 50 nM staurosporine only (a) or in presence of 30 µM SB-415286 (b). E-lams are marked with arrows. Scale bar: 10 µm.

 


View larger version (39K):

[in a new window]
 
Fig. 6. The localization of GSK-3 in E-lams. Immunolocalization of GSK-3 in control (A) and staurosporine-treated (B,C) cells. GSK-3 accumulated in the extended part of the E-lam is marked with arrows. In A and B GSK-3 was visualized by immunofluorescence, whereas in C, GSK-3 was detected by biotin-avidinperoxidase complex using VIP as a chromogen. To help visualize the cell shape, partial outlines of cells are marked with dashed lines. Scale bar: 10 µm.

 


View larger version (30K):

[in a new window]
 
Fig. 7. The role of intracellular free Ca2+ in E-lam formation. (A) The spread cells were loaded with fura-2, and the ratio of 346/380 nm excitation indicating the level of intracellular free Ca2+ was measured by fluorimetry. Stable baseline Ca2+ was obtained for 50 seconds before the addition of staurosporine. A typical response is shown. (B) To study the role of intracellular free Ca2+, the spread cells were treated with Ca2+ chelators 2 mM EGTA or BAPTA-AM (0-10 µM) in presence or in absence of staurosporine and analyzed for cell spreading and E-lam formation. The results show the mean±s.d. of a typical experiment (n=8). (*P<0.05; **P<0.01; ***P<0.001.)

 


View larger version (35K):

[in a new window]
 
Fig. 8. The role of PLC-{gamma}1 in E-lam formation. (A) To study the role of PLC-{gamma} in E-lam formation, the spread cells were treated with PLC inhibitor U-71322 (0-4 µM) in the presence or in absence of staurosporine and analyzed for cell spreading and E-lam formation. The results show the mean±s.d. of one typical experiment (n=8). (*P<0.05; **P<0.01; ***P<0.001.) (B) Immunolocalization of tyrosine phosphorylated (active) PLC-{gamma}1 (a,b) and actin (c,d) in control (a,c) and staurosporine-treated (b,d) cells. PLC-{gamma}1 and actin accumulated in E-lams are marked with arrows and arrowheads, respectively. Scale bar: 10 µm.

 


View larger version (29K):

[in a new window]
 
Fig. 9. The effect of Ca2+ modulators on GSK-3 phosphorylation. The cells were allowed to spread on fibronectin for 120 minutes and then treated with 50 nM of staurosporine alone (G,H) or together with thapsigargin (100 nM; A,B), PLC-{gamma}1 inhibitor U-71322 (4 µM; C,D) or BAPTA-AM (10 µM; E,F) for either 0-60 minutes or left untreated for 60 minutes (C60'). The cell lysates were separated by SDS-PAGE and immunoblotted with antibodies recognizing GSK-3{alpha}/ß phosphorylated on serine 21/9 (A,C,E,G) or total GSK-3 (B,D,F,H).

 


View larger version (188K):

[in a new window]
 
Fig. 10. Effect of GSK-3 inhibitors on cell migration. Confluent cell layers were scratch-wounded and then treated with staurosporine (50 nM; B,E,H), EGF (10 ng/ml; C,F,I) or left untreated (A,D,G) together with GSK-3 inhibitors SB-415286 (30 µM; D-F) and LiCl2 (30 mM; G-I) for 24 hours. In EGF-treated samples, the wounded cultures were preincubated for two hours before adding EGF to the samples. The cells were then fixed, stained with crystal violet and photographed. Scale bar: 100 µm.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




© The Company of Biologists Ltd 2003